Reyon Pharmaceutical Co (XKRX:102460) Net Income From Continuing Operations : ₩616 Mil (TTM As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Reyon Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Reyon Pharmaceutical Co's net income from continuing operations for the three months ended in Sep. 2024 was ₩619 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2024 was ₩616 Mil.

Reyon Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Reyon Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reyon Pharmaceutical Co Net Income From Continuing Operations Chart

Reyon Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

4,944.36

3,844.43

5,537.25

7,433.68

3,583.37

Reyon Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-100.92	-989.36	326.17	659.65	619.34

Reyon Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩616 Mil.

Reyon Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Reyon Pharmaceutical Co Ltd (XKRX:102460) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

416, Yeongdong-daero, 8th floor, Gangnam-gu, Seoul, KOR

Website

http://reyonpharm.co.kr

Reyon Pharmaceutical Co Ltd is a Korea-based pharmaceutical company. It is engaged in the manufacturing and distribution of specialty medicines and raw materials. The main business of the company has been divided into generic drugs, original drugs, and drug substances The key products include eye drops, injection, antibiotics, skeletal muscle relaxants, coagulation drugs, anti-inflammatory enzymes, and blood vessels dialectic drugs, among others.

Reyon Pharmaceutical Co Headlines

No Headlines